HOME    | Hepatitis B     | Hepatitis C  
<--- Return to the 56th AASLD Main Page
HIVandHepatitis.com Coverage of Highlights from the
56th Annual Meeting of the American
Association for the Study of Liver Diseases
 November 11 - 15, 2005 San Francisco, California


Pharmacokinetics

SCH 503034, an Experimental HCV Protease Inhibitor from Schering Plough, Shows Potent Anti-HCV Activity in Patients Previously Failing on Peginterferon Alfa - 11/14/05

Pharmacokinetics and Safety of the Experimental, Oral HCV Protease Inhibitor SCH 503034 in Healthy Subjects - 11/14/05

SCH 503034 Suppresses Polyprotein Maturation and Enhances the Antiviral Activity of Interferon Alfa-2b - 11/14/05

No Effect of Pegylated Interferon Alfa-2b (PegIntron) on the Pharmacokinetics of Valopicitabine (NM 283) in Chronic HCV Patients - 11/14/05



<--- Return to the 56th AASLD Main Page